Global Multiple Sclerosis Market will expand steadily from 2009 to 2024 - new report explains The multiple sclerosis (MS) market has total global revenues of over $6bn in 2008. Those revenues will exceed $9bn during the second half of next decade, our new study shows. The World Health Organization estimates that over 2.5 million people suffer from multiple sclerosis worldwide. The prevalence and onset of MS in children and a...
More »
Search ReportLinker
The Largest Collection of Market Research Reports
» 1.2 Million Industry Reports
» 450,000 Company Profiles
» 850,000 Market Briefings
» 40,000 Country Guides
From +200,000 authoritative sources
Global Multiple Sclerosis Market will expand steadily from 2009 to 2024 -
new report explains
The multiple sclerosis (MS) market has total global revenues of over $6bn in
2008. Those revenues will exceed $9bn during the second half of next decade,
our new study shows. The World Health Organization estimates that over 2.5
million people suffer from multiple sclerosis worldwide. The prevalence and
onset of MS in children and adults is expected to rise steadily. Global
sales for MS therapies will rise accordingly, due to epidemiological,
healthcare and commercial drivers. In this new market-based study - The
Global Multiple Sclerosis Market 2009-2024 - we show and explain those
trends in detail. This report will provide you with the analytical
information that you need to understand current trends and future directions
in the MS market area, the successful drugs being introduced and where the
future successful growth of the market lies.
The Global Multiple Sclerosis Market 2009-2024 commercially analyses both
leading and emergent treatments, with key companies and products discussed
comprehensively. In particular, we discuss prospects for the following MS
drugs:
- Tysabri
- Avonex
- Copaxone
- Betaferon
- Rebif.
Contemporary disease-modifying drugs for MS are administered intravenously,
intramuscularly or subcutaneously, typically with discomfort to patients. We
believe that orally-administered MS products will change the dynamics of the
market area significantly. But you must understand now the commercial
opportunities for those new agents and other exciting pipeline developments.
This report answers those important questions and others, such as how the
established MS products will fare competitively in the years ahead. Which
will remain the most profitable and how will they be affected by new
competition.
Comprehensive Market Analysis
The Global Multiple Sclerosis Market 2009-2024 examines the market sector
critically through a comprehensive review of information sources, including
first-hand primary consultations with relevant experts. This report provides
detailed sales forecasts, discussions of pipeline developments and analyses
of important contemporary issues, especially relevant commercial drivers and
restraints. Sources used include gold-standard commercial databases,
in-house analytical tool, industry news, published reports, policy documents
and economic research. Importantly, visiongain applies rigorous financial
forecasting, qualitative analyses and the assessment of unmet needs. The
result is a comprehensive market- and industry-centred report with detailed
analysis and informed opinion.
Why you should buy the Global Multiple Sclerosis Market 2009-2024 By
purchasing this report, you will receive the following benefits:
Predicted revenues, growth rates and other key metrics for the global MS
drugs market from 2009 to 2024 Predicted revenues, growth rates and other
key metrics for leading MS drugs worldwide from 2009 to 2024 Predicted
revenues, growth rates and other key metrics for MS drug sales in leading
nations from 2009 to 2024 Expert opinions from original visiongain
interviews, with full interview transcripts - you will not find this
information anywhere else Discussion of hot pipeline developments and
up-and-coming products Discussion of forces that influence and characterise
the market for MS treatments worldwide:
* Competitive characteristics of the market
* Drivers
* Restraints
* Strengths, weaknesses, opportunities and threats
Discussion of where the market is heading overall - both technologically and
commercially - from the present onwards.
Nobody with an interest in the MS sector can afford to overlook this new
market study from visiongain. Visiongain predicts that total revenues in the
MS market will increase steadily throughout the forecast period, 2009 to
2024, with the most substantial growth occurring during a crucial period in
the future. The market environment in many countries will change, with
patent losses affecting current market leaders in MS treatment. New drug
releases and reformulations of products will seek to increase therapeutic
effectiveness, especially patient compliance. A new wave of oral drugs,
currently in development, may well change the way MS treatments are
delivered.
Global Pharmaceutical Industry
Table of Contents
1 Executive Summary
1.1 Multiple Sclerosis Market Review
1.2 Aims, Scope and Format of the Report
2 Introduction to Multiple Sclerosis
2.1 The Biology of MS
2.2 The Disease
2.2.1 Symptoms of MS
2.2.2 Diagnosis of MS
2.3 Measuring MS
2.3.1 The Kurtzke Expanded Disability Status Scale (EDSS)
2.4 The Different Types of MS
2.4.1 Relapsing-Remitting MS
2.4.2 Secondary Progressive MS
2.4.3 Progressive Relapsing MS
2.4.4 Primary Progressive MS
2.4.5 Other Atypical Presentations
2.5 Causational Factors of MS
2.5.1 Genetic Factors
2.5.2 Infection
2.5.3 Environmental Factors and Less Supported Theories
2.6 World Demographics and Economic Costs of MS
2.7 Treatment Options
2.7.1 Alternative Treatments
2.7.2 Medical Approaches
2.8 Pharmacotherapy
2.8.1 Treatment of Acute Symptomatic Attack
2.8.2 Disease-Modifying Treatments
3 The Market for MS Drugs 2009-2024
3.1 MS Market Analysis
3.2 The Leading MS Drugs - Overall Sales Comparisons
3.3 Biogen's Avonex was Top-Selling MS Drug - How will it Fare?
3.3.1 Avonex Sales from 2009 to 2024
3.3.2 Patent Expiry in Major Markets Will Impact on Revenues
3.3.3 How Will Increased Competition Affect Sales from 2010 Onwards?
3.4 Will Copaxone's Revenues Increase Despite Competitive Threats?
3.4.1 Copaxone and Direct Competition
3.4.2 Will Product Development Increase Market Potential?
3.4.3 Competition Resulting from Newer Therapies and Patent Expiry - What
Effects on Sales?
3.5 Will Rebif's Efficacy and Drug Delivery Lead to Market Dominance?
3.5.1 Will Novel Delivery Mechanism Drive Sales in the Retail Sector?
3.5.2 Rebif's Sales During Forecast Period
3.6 Betaferon Faces Patent Expiry During the Forecast Period
3.6.1 Will Betaferon Be Competitive Enough in the Market?
3.7 Will Re-Launched Tysabri Generate Blockbuster Sales?
3.7.1 Two New PML Cases May Erode Sales
3.7.2 Tysabri (natalizumab) for Oncology
3.8 Prospects for the Oral MS Drug Market
3.9 MS Market Summary 2009-2024
4 The Market for MS Drugs in the Seven Major Markets, 2009-2024
4.1 MS Drugs in the Seven Major Markets: Analysis
4.2 MS Market in the US
4.2.1 Leading MS Products in the US Market
4.2.2 Market Drivers
4.2.3 Market Restraints
4.3 MS Market in Germany
4.3.1 Leading MS Products in the German Market
4.3.2 Market Drivers
4.3.3 Market Restraints
4.4 MS Market in France
4.4.1 Leading MS Products in the French Market
4.4.2 Market Drivers
4.4.3 Market Restraints
4.5 MS Market in Italy
4.5.1 Leading MS Products in the Italian Market
4.5.2 Market Drivers
4.5.3 Market Restraints
4.6 MS Market in Canada
4.6.1 Leading MS Products in the Canadian Market
4.6.2 Market Drivers
4.6.3 Market Restraints
4.7 MS Market in Spain
4.7.1 Leading MS Products in the Spanish Market
4.7.2 Market Drivers
4.7.3 Market Restraints
4.8 MS Market in the UK
4.8.1 Leading MS Products in the UK Market
4.8.2 Market Drivers
4.8.3 Market Restraints
5 An Analysis of Factors that Influence the Global MS Market
5.1 SWOT Analysis of the MS Market 2009-2024
5.2 Market Drivers
5.3 Market Restraints
5.4 The MS Market Has Opportunities for Continuing Growth
5.5 Entry of Oral MS Drugs Will Provide More-Accessible Treatment Options
5.6 Advances in Technology Likely to Bring Benefits to the Market
5.7 Comparative Studies - a Two-Edged Sword
5.8 Important Patient Sub-Populations: Potential for Companies to Increase
Market Leverage Through Product Differentiation
5.9 Concerns Over the High Price of Treatments - Who Yields the Power?
5.10 A Discussion of Generic Drugs in This Market - How Great is Their
Threat?
5.11 How Much Scope is There to Improve Safety and Tolerability in MS Drugs?
6 Leading Companies in MS Therapy Development
6.1 Key Companies Delivering MS Therapies Highlighted
6.1.1 Biogen Idec and Elan Pharmaceuticals
6.1.2 Merck Serono
6.1.3 Bayer-Schering
6.1.4 Sanofi-Aventis and Teva
7 Pipeline Drugs for MS
7.1 MS Pipeline Drugs
7.2 The Potential Treatment Options in MS
7.2.1 Reducing Inflammatory Response
7.2.2 Managing Autoimmune Response
7.2.3 Manipulating the Permeability of the Blood-Brain Barrier
7.2.4 Inhibiting Demyelination
7.2.5 Protection Axons from Damage
7.2.6 Encouraging Remyelination
7.3 Drugs that Regulate Immune Response by Destroying Lymphocytes
7.3.1 Fingolimod (FTY720)
7.3.2 Mylinax (Oral Formulation)
7.3.3 Alemtuzumab
7.3.4 Rituximab
7.4 Drugs that Manage Immune Activity
7.4.1 Teriflunomide
7.4.2 Laquinimod
7.4.3 Daclizumab
7.4.4 MBP 8298
7.4.5 Integrin Inhibitors
7.5 Drugs that Reduce Inflammation
7.5.1 BG-12
7.5.2 MLN 1202
7.5.3 Ibudilast
7.6 MS Vaccines
7.6.1 Tovaxin
7.6.2 BHT-3009
7.7 Drugs to Improve Nerve Function
7.7.1 Fampridine-SR
7.7.2 Lamotrigine
7.8 Pfizer's Lipitor (atorvastin) and Other Statins
7.9 GW Sativex Investigational Cannabis-Based Treatment for MS 7.10 An "Oral
Drug Revolution" in MS Treatment - a Possibility?
7.11 MS Pipeline Shows Short- and Long-Term Potential
7.12 The Future of MS Treatments
7.12.1 Stem Cell Therapy
7.12.2 Thyroid Hormone has Treatment Potential
8 Experts' Views
8.1 Interview with Dr. Rosie Jones from Bristol General Hospital, MS
Research Unit, UK
8.1.1 Introduction
8.1.2 Understanding MS
8.1.3 On Disease-Modifying Treatments
8.1.4 On Oral Drugs
8.1.5 On the Problems of Long-Term Treatments
8.1.6 On Natalizumab (Tysabri) and Progressive Multifocal
Leukoencephalopathy (PML)
8.1.7 On Alternative Treatments
8.1.8 On Medical Marijuana Use
8.1.9 The Future of MS Treatments
8.2 Interview with Dr Johan Luthman (Merck Serono)
8.2.1 On Understanding the Disease and its Treatment
8.2.2 On Unmet Needs for MS Therapy
8.2.3 On Current Treatment Options
8.2.4 On Medical Marijuana Use
8.2.5 On Oral Drugs
8.2.6 On Future Treatment Possibilities
8.3 Second Interview with Dr Johan Luthman (Merck Serono), Specifically
Concerning Stem Cell Potential in MS
8.3.1 On Stem Cell Media Coverage
8.3.2 On the Therapeutic and Curative Potential of Stem Cells for
Neurological Disorders
8.3.3 On the Treatment of Neurological Disorders
8.3.4 On Stem Cell Treatment of MS - Viability, Curative Power, Treatment
Strategy and Results
8.3.5 On the Timeframe for Marketable Stem Cell Treatment Options
8.4 Concluding Thoughts
8.4.1 Concerning Symptom Management
8.4.2 Concerning Current Treatments and Patient Sub-Groups
8.4.3 Concerning Oral Drugs
8.4.4 Concerning Stem Cell Treatment
9 Conclusions
9.1 The MS Market Will Achieve Continued Growth
9.2 Great Scope for an Oral MS Drug to Enter the Market
9.3 Major Players in the MS Market
9.4 Market Drivers
9.5 Market Restraints
9.6 MS Market - Overview
List of Tables
Table 2.1 The Kurtzke Expanded Disability Scale Table 3.1 The Total Market
for MS Drugs: Revenue ($m) Forecast, 2009-2024 Table 3.2 Revenues ($m),
7-Year CAGR (%) and Market Share (%) for the Leading MS Drugs, 2007 & 2014
Table 3.3 Top 5 MS Products Rank Comparison, 2007 and 2024 Table 4.1 MS
Drugs: Revenue ($m) Forecast in the Seven Major Markets,
2009-2024
Table 4.2 The Leading MS Drugs in the US Market, 2007 Table 4.3 The Leading
MS Drugs in the German Market, 2007 Table 4.4 The Leading MS Drugs in the
French Market, 2007 Table 4.5 The Leading MS Drugs in the Italian Market,
2007 Table 4.6 The Leading MS Drugs in the Canadian Market, 2007 Table 4.7
The Leading MS Drugs in the Spanish Market, 2007 Table 4.8 The Leading MS
Drugs in the UK Market, 2007 Table 5.1 A SWOT Chart for the MS Market,
2009-2024 Table 6.1 Top 5 Companies in the MS Market, 2007 Table 7.1 MS
Pipeline Drugs: Phase II and Beyond, 2008
List of Figures
Figure 3.1 The Total MS Market: Revenue ($m) Forecast, 2009-2024 Figure 3.2
The Leading MS Drugs: Market Revenue ($m) Forecast, 2009-2024 Figure 3.3
Leading MS Drugs: Revenue ($m) by Sector, 2007 Figure 3.4 Leading MS Drugs:
Market Share (%), 2007 Figure 3.5 Leading MS Drugs: Market Share (%), 2014
Figure 3.6 Avonex Revenue ($m) Forecast 2009-2024 Figure 3.7 Copaxone
Revenue ($m) Forecast 2009-2024 Figure 3.8 Rebif Revenue ($m) Forecast
2009-2024 Figure 3.9 Betaferon Revenue ($m) Forecast 2009-2024 Figure 3.10
Tysabri Revenue ($m) Forecast 2009-2024 Figure 4.1 The US MS Market Revenue
($m) Forecast, 2009-2024 Figure 4.2 The German MS Market Revenue ($m)
Forecast, 2009-2024 Figure 4.3 The French MS Market Revenue ($m) Forecast,
2009-2024 Figure 4.4 The Italian MS Market Revenue ($m) Forecast, 2009-2024
Figure 4.5 The Canadian MS Market Revenue ($m) Forecast, 2009-2024 Figure
4.6 The Spanish MS Market Revenue ($m) Forecast, 2009-2024 Figure 4.7 The UK
MS Market Revenue ($m) Forecast, 2009-2024 Figure 9.1 Total Revenues ($m)
for MS Drugs, 2009-2024
Companies Mentioned in this Report
Active Biotech
Acorda Therapeutics
Aegera Idera
Allergan
Antisense Therapeutics
Apitope
Argyll Biotechnologies
Asphelia
Bayer-Schering
Bayhill Therapeutics
Berlex Laboratories
Biogen Idec
BioMS
BioPartners
BTG
Elan Pharmaceuticals
Eli Lilly
Fornix
GemacBio
Genentech
GlaxoSmithKline
GW Pharmaceuticals
IMS
Indevus
InterMune
Isis
Manhattan
Medarex
MediciNova
Merck KGaA
Merck Serono
Millennium
Mitsubishi Tanabe Pharma
Momenta Pharmaceuticals
Mylan
Natco Pharmaceuticals
Neuren
Novartis
Opexa
Orchestra Therapeutics
Otsuka Pharmaceuticals
PDL BioPharma
Pfizer
ReceptoPharm
Rentschler
Roche
Sanofi-Aventis
Teva
Transition
UCB
